Targeting Histone Modifications in Bone and Lung Metastatic Cancers.

ABSTRACT:

Purpose of review

Breast cancer frequently metastasizes to the bone and lung, but the ability to treat metastatic tumor cells remains a pressing clinical challenge. Histone deacetylases (HDACs) and histone acetyltransferases (HATs) have emerged as promising targets since these enzymes are aberrantly expressed in numerous cancers and regulate the expression of genes that drive tumorigenesis and metastasis. This review focuses on the abnormal expression of histone-modifying enzymes in cancers that have a high tropism for the bone and lung and explores the clinical use of histone deacetylase inhibitors for the treatment and prevention of metastasis to these sites.

Recent findings

Preclinical studies have demonstrated that the role for HDACs is highly dependent on tumor type and

SUBMITTER: Edwards CM 

PROVIDER: S-EPMC8316289 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature